b'Colorados Premier Life Sciences Incubator: From Startup to Scale Build an investor-ready company with a proven commercialization frameworkFast- track your commercialization with targeted education and expertise thatshortens time to market 50 Startups GraduatedGet in front of investors, partners, and industry leaders who can fuel yournext stage of growth. $34,770,000 Total RaisedInnophere also offers flexible commercial offices and lab space to supportyour companys growth from idea to scale 14 59 33Patents Provisional FiledInnosphere can take you from being really ambitious but unfocused Patentsand help focus those efforts, preventing you from spinning yourwheels and wasting a lot of money and time. It starts making progresstowards actual goals that will get you towards commercialization.Turn Breakthrough Science intoMarket Success. Apply Now! Blake Hyde, CEO and Founder www.innosphere.org Decorum Medical InnovationsDiving into a fresh Grand Challenge, StollHer teams original breakthrough discoveryright order and I have all of these resources decided to focus on identifying the uniquewas announced in 2016 and since then,around me, Stoll says. Numiera Therapeutics vulnerabilities of cancer cells, in order tofour other labs globally have replicated thewasrecentlyawardedastate-funded develop better treatments for aggressiveresults. Acknowledging the strong scientificAdvanced Industries Accelerator Grant, has tumors. The advanced state of science ledconsensusaroundthistarget,theFDAgraduated from the Innosphere Life Sciences her to form Numiera Therapeutics, where shehas awarded Numiera Therapeutics withIncubation Program, and participates in the serves as cofounder and CEO. The companyan orphan drug designation. Through thisstates Advanced Industry Investment Tax is now on the cutting edge of treating brainpathway, the drug can be repurposed for anCredit program. tumors with a repurposed drug that stopsurgent disease designation and it is eligible cancers from converting fatty acids into energy.for seven years of post-approval marketI got the right Stoll, trained as a neuroscientist, had beenexclusivity, tax credits, fee waivers, and researching how energy is distributed to workaccelerated clinical trials. The FDA recognizedsupport in the in complex biological systems. If you follow howthe strong clinical potential of this drug and energy is moved around and used in systems awarded it a broader designation than Stollright order and cells, organisms, or entire ecosystemsyouand her team had requested. It is now desig-nated for all gliomas and has the potential to know exactly what the system is doing.change the treatment of aggressive cancers. I have all of She was motivated to find a way to halt cancer cells without harming normal healthy cellsThe idea that we could have a drug that reallythese resources and looked for a mechanism to stop cancerstops cancer cells in their tracks, but doesnt cause all of these other terrible side effects, cells metabolic activity. She found it in ais really hopeful, Stoll says. around me.small-molecule therapy approach that blocks the transfer of fatty acids into the mitochondriaStoll credits the environment of life sciences and prevents the cells from making thestartups in Colorado for much of her com- IZI STOLL, Ph.D. COFOUNDER AND CEO energy to support their malignant growth.panys growth: I got the right support in theNUMIERA THERAPEUTICS2025-2026 BIOSCIENCE COLORADO 39'